# Rivaroxaban in Patients With Atrial Fibrillation Undergoing PCI

> **NCT03315650** · — · COMPLETED · sponsor: **IHF GmbH - Institut für Herzinfarktforschung** · enrollment: 1632 (actual)

## Conditions studied

- Non-valvular Atrial Fibrillation
- Acute Coronary Syndrome
- Percutaneous Coronary Intervention
- Antithrombotic Therapy

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03315650
- **Lead sponsor:** IHF GmbH - Institut für Herzinfarktforschung
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-01
- **Primary completion:** 2020-03-31
- **Final completion:** 2021-06-24
- **Target enrollment:** 1632 (ACTUAL)
- **Last updated:** 2022-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03315650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03315650, "Rivaroxaban in Patients With Atrial Fibrillation Undergoing PCI". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03315650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*